Page 16 - ITPS-6-1

10 INNOSC Theranostics and Pharmacological Sciences, 2023, Vol. 6, No. 1 Vishwakarma, et al.
to vehicle control that was largely restored by
LDL Ch./HDL Ch. ratio (mg/dL) 0.45±0.02 1.42±0.05* 0.58±0.07* # 0.70±0.06* #$ 0.67±0.02* #$ reduced compared to vehicle control. Exceptionally
metformin (500 mg/kg) treatment yet statistically
AEPO was unable to show statistical alterations in
the HDL level as compared to STZ-diabetic rats.
Ch.: Cholesterol; AEPO: Aqueous extract of Pleurotus ostreatus; STZ: Streptozotocin. *P<0.05 versus control; # P<0.05 versus STZ group; $ P<0.05 versus metformin group
We further assessed the kidney function profile
of different experimental groups and data are
Total Ch./HDL Ch. ratio (mg/dL) 1.73±0.09 2.84±0.27* 1.86±0.04* # 2.46±0.08* #$ 2.31±0.09* #$ all the diabetic rats showed altered levels of kidney
presented in Table 6. Results clearly indicate that

function parameters. In a nutshell, results showed
that the levels of serum creatinine, serum uric acid,
serum urea, and serum blood urea nitrogen (BUN)
were elevated multifold in STZ-diabetic rats with

VLDL Ch. (mg/dL) 4.82±0.86 26.94±1.25* 13.64±0.92* # 17.50±0.88* #$ 16.44±0.42* #$ statistical significance. Treatment with metformin
(500 mg/kg) to diabetic rats was preventive in
nature to larger extent yet statistically not closer to
vehicle control or STZ-diabetic group. Likewise,
administration of diabetic rats with AEPO showed
a dose-dependent restoration of kidney function
LDL Ch. (mg/dL) 17.76±1.22 45.16±2.01* 19.78±1.85* # 28.77±1.51* #$ 26.75±1.85* #$ parameters yet statistically not closer to vehicle
control or STZ-diabetic group.

4. Discussion
Table 5. Effect of AEPO and metformin on lipid profile of experimental rats
HDL Ch. (mg/dL) 42.1±1.05 31.9±1.22* 39.7±1.51* # 32.1±1.62* $ 33.5±1.25* Values are mean±SEM for groups of three observations with their standard errors. HDL: High-density lipoprotein; LDL: Low-density lipoprotein; VLDL: Very-low-density lipoprotein; Diabetes mellitus is one of the most common chronic
diseases associated with carbohydrate metabolism.
It is also an indication of co-morbidities such as
obesity, hypertension, and hyperlipidemia, which
are metabolic complications of both clinical and
Triglyceride (mg/dL) 24.1±1.54 134.7±1.22* 40.23±1.87* # 89.91±1.54* #$ 68.2±0.98* #$ experimental diabetes [26]. At present, drug therapy
either alone or in combination cannot restore
normal blood glucose homeostasis, and many
limitations exist in their use. While external insulin
is necessary for control of type 1 diabetes mellitus,
Total cholesterol (mg/dL) 58.5±1.02 138.63±1.98* 73.9±1.81* # 90.7±0.99* #$ 78.52±1.58* #$ the use of drug therapy in type 2 diabetes is initiated
only after dietary and lifestyle modifications [13].
Oyster mushroom (Pleurotus spp.) is known in
the Indian traditional system of medicine for
its antihyperglycemic and antihyperlipidemic
potential. P. ostreatus is reported to contain several
bioactive molecules that are attributed to its
therapeutic effects. The major bioactive molecules
are phenolics, flavonoids, polysaccharides, lectins,
Experimental groups Vehicle control STZ-induced (diabetic) Diabetic+metformin (500 mg/kg) Diabetic+AEPO (100 mg/kg) Diabetic + AEPO (200 mg/kg) terpenoids, steroids, lipids, and glycoproteins.
These phytochemical compounds act as exogenous
antioxidants that can regulate oxidative stress,
suppress inflammation, and regulate glycemic and
lipidemic alterations in the human body [27]. By
virtues of the benefits of oyster mushrooms, we
attempted to explore the effects of an AEPO on

©2023 AccScience Publishing